Navigation Links
Pasteuria Bioscience to be Acquired by Syngenta
Date:9/19/2012

ALACHUA, Fla., Sept. 19, 2012 /PRNewswire/ -- Pasteuria Bioscience has announced that it will be acquired by Syngenta, one of the world's leading agricultural technology companies.  In 2011 Syngenta and Pasteuria Bioscience entered into a global exclusive technology partnership to produce nematode control products based on Pasteuria spp., a naturally-occurring soil bacteria long recognized as a promising biological control agent against nematodes.  The first products resulting from this relationship will be available in 2014.

Under terms of the agreement, Syngenta will acquire Pasteuria Bioscience for aggregate payments of $86 million, plus up to $27 million in deferred payments.

"Pasteuria Bioscience is excited to become part of the Syngenta team.  We've been working closely together over the past year and have made significant progress on a number of nematode control products in a variety of crops.  Syngenta recognizes the potential with the Pasteuria platform and can commercialize it in a broad range of products for the global marketplace," said Al Kern, Executive Chairman and President of Pasteuria Bioscience.

Nematodes are a major pest across all crops and there are few commercial products available making it one of agriculture's largest unmet pest control needs.  This acquisition will facilitate the introduction of key products, including a seed treatment product for Soybean Cyst Nematode (SCN) which will complement Syngenta's existing nematicide line. 

"Results from our partnership have shown that Pasteuria provides superior control of nematodes in a wide variety of applications.  Pasteuria Bioscience has developed critical knowhow for in vitro production of Pasteuria, enabling commercial scale manufacturing.  This is a further example of our strategy to incorporate biological controls within our integrated offer to growers," said John Atkin, COO of Syngenta.

About Pasteuria Bioscience

Pasteuria Bioscience, Inc., was founded in 2003 in the University of Florida's Sid Martin Biotechnology Incubator where it remains headquartered.  The company was developed to commercialize its revolutionary technology for production of biological nematode control products based on the Pasteuria platform.  The first Pasteuria-based product, Econem®, was commercialized in 2010 for sting nematode control in the golf and sports turf markets.  Pasteuria Bioscience is also developing products to treat major nematode pests in most agricultural crops such as soybean, sugar beet and cotton as well as in specialty crops such as fruits and vegetables.  For more information, visit the Pasteuria Bioscience web site at http://www.pasteuriabio.com.

Note to the editor:

Learn more about Syngenta http://www.syngenta.com.


'/>"/>
SOURCE Pasteuria Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta to acquire Pasteuria Bioscience
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
5. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
6. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Roka Bioscience Secures $47.5 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... 2017  SeraCare Life Sciences, Inc., a manufacturer ... diagnostics manufacturers and clinical laboratories, is announcing ... Inherited Cancer reference material for ... sequencing (NGS). The Seraseq™ Inherited Cancer DNA Mix ... industry experts to validate the ability of ...
(Date:3/23/2017)... Calif., March 23, 2017  BioPharmX Corporation (NYSE ... for the dermatology market, today reported financial results ... 2017, and will provide an update on the ... year. "We are pleased to report ... for BioPharmX," said President Anja Krammer. "We achieved ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):